Coronavirus Recent: Paltrow Store in San Francisco Goop Closed, becoming the most recent commercial market

CureVac says it will continue to be accepted by Europeans to protect against coronavirus vaccines even if they are disappointed with the results, saying the final review of the trial shows a 77% protection against serious illnesses and adequate hospital and mortality protection.

In early June, shares in the German biopharmaceutical company fell by almost 50% after its long-term experience showed an increase of 47%, a slight decrease in competitors Moderna and BioNTech who also produced jabs messenger ribonucleic acid (mRNA ).

The last CureVac analysis reported by Nasdaq showed a 48% increase against Covid-19 in any strength, and 53% against mild disease. In a study of 18- to 60-year-olds, he said that efforts to combat chronic diseases meant that he still had a way to get his CVnCoV vaccine approved by the European Medicines Agency.

“Finally, CVnCoV demonstrates the benefits of public health in protecting participants between the ages of 18 and 60 in hospital and death and 77% against chronic diseases – a useful history, which we believe will be an important aid in combating the Covid-19 epidemic and vigorous spread,” says Franz-Werner Haas, chief.

CureVac says its mRNA vaccine activity, which is being developed with the help of giant drug giant Bayer, was low because it uses 15 different types of viruses. About 86% of cases of coronavirus in its trials came from species that the World Health Organization listed as “diverse needs” or “species of pleasure”. But recent research has also shown a significant interaction between other vaccines.

Haas said the CureVac case, which studied about 40,000 in Europe and Latin America, also provides important information on several species of coronavirus. Nearly all people who have been exposed to the virus have experienced the first coronavirus infection, while 11%, the company said, were a minority of the virus.

Earlier this month, CureVac adauza tHe Financial Times may seek the approval of certain age groups, its strengths, or its potential as a shooter. It also stated that a second-generation anti-virus vaccine, developed by GlaxoSmithKline, should not be affected by its adverse effects of the vaccine, as it was designed differently.